Please assess the completion status of the following clinical trial:

Trial Title: Fenretinide in Healthy Young Women at Genetic and Familial Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 20-46 years old women with a known BRCA ½ mutation or with a risk of being a mutation carrier ≥20%.~2. Performance status =0~3. Willingness to avoid pregnancy during treatment and 12 months after drug cessation~4. No clinical and radiological evidence of breast cancer and ovarian disease~5. Signed informed consent~Exclusion Criteria:~1. History of breast cancer or any other malignancy with the exclusion of CIN and non-melanoma skin cancer~2. Child bearing or breast feeding~3. Genetic test result (BRCA)=true negative~4. Blood test alterations (grade ≥2 based on the NCI Common Toxicity Criteria)~5. Previous or concurrent use of SERMs, e.g. tamoxifen (for more than 12 months; if less, a two-months wash-out is required before entering the study)~6. Severe psychiatric disorders or inability to comply to the protocol procedures~7. Any other factor that, at the investigator's discretion, contraindicates the use of fenretinide

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Fenretinide (Type: EXPERIMENTAL): 100mg: 2cps/day for 5 years followed by
- Placebo (Type: PLACEBO_COMPARATOR): matched placebo 2 cps/day for 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).